Boehringer Ingelheim emphasized the importance of open innovation and announced that it has a long-term partnership with Yuhan. It also mentioned the possibility of further open innovation for R&D materials in Korea. In addition, they expressed their will to do their best in the development of COVID-19 treatment and anticancer drugs targeting KRAS.

Boehringer Ingelheim held an online global annual press conference on the morning of the 24th (local time in Germany) and announced last year's results and forecasts for this year.

In spite of COVID-19 crisis, Boehringer Ingelheim showed good performance last year with its flagship items, Jardiance and Ofev. Total sales amounted to €19,570 mi